5th Feb 2015 08:46
LONDON (Alliance News) - Futura Medical PLC on Thursday said the US Patent & Trademark Office has granted a three-year extension to the patent protection for its MED2002 product.
MED2002 is Futura's topical gel for the treatment of erectile dysfunction.
The patent extension has been granted to cover the product until August 2028.
"We are very pleased to be awarded this three-year patent extension from the US Patent & Trademark Office for MED2002. This patent extension is potentially highly significant as, assuming US regulatory approval during 2018, it lengthens MED2002's commercial window by around 40 per cent in the world's largest pharmaceutical market," said Futura Chief Executive James Barder.
Futura shares were untraded on Thursday morning, having last traded at 29.00 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Futura Medical